Research Analysts Set Expectations for Amgen FY2025 Earnings

Amgen Inc. (NASDAQ:AMGN - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for shares of Amgen in a report issued on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now expects that the medical research company will post earnings per share of $20.90 for the year, up from their previous forecast of $20.85. Cantor Fitzgerald has a "Neutral" rating and a $305.00 price objective on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share. Cantor Fitzgerald also issued estimates for Amgen's FY2026 earnings at $21.47 EPS.

Several other research firms have also issued reports on AMGN. William Blair reiterated an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. Guggenheim initiated coverage on Amgen in a report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 target price on the stock. Mizuho lifted their price target on Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, May 7th. Wall Street Zen upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Finally, UBS Group reaffirmed a "neutral" rating and issued a $315.00 price objective (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of "Hold" and a consensus price target of $307.82.

Amgen Price Performance

AMGN stock traded down $5.10 during mid-day trading on Thursday, hitting $295.27. The stock had a trading volume of 1,619,752 shares, compared to its average volume of 2,847,778. The firm has a fifty day simple moving average of $283.56 and a 200 day simple moving average of $288.31. The firm has a market capitalization of $158.77 billion, a P/E ratio of 26.94, a P/E/G ratio of 2.67 and a beta of 0.49. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. Amgen has a 52 week low of $253.30 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The firm had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same quarter last year, the company earned $3.96 EPS. The company's revenue was up 9.4% on a year-over-year basis.

Institutional Investors Weigh In On Amgen

Several institutional investors and hedge funds have recently made changes to their positions in AMGN. Vanguard Group Inc. lifted its position in shares of Amgen by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 52,870,453 shares of the medical research company's stock worth $16,471,790,000 after purchasing an additional 148,658 shares during the period. Geode Capital Management LLC increased its position in shares of Amgen by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company's stock worth $3,245,881,000 after buying an additional 352,143 shares during the period. Capital International Investors raised its stake in Amgen by 40.1% during the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after buying an additional 3,495,503 shares during the last quarter. Capital World Investors lifted its holdings in Amgen by 1,292.0% in the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after buying an additional 6,029,058 shares during the period. Finally, Northern Trust Corp lifted its holdings in Amgen by 15.8% in the fourth quarter. Northern Trust Corp now owns 6,431,029 shares of the medical research company's stock valued at $1,676,183,000 after buying an additional 875,254 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president directly owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.69% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.